ElevateBio Announces AlloVir As First Spoke In Its Cell And Gene Therapy Hub
ElevateBio revealed the first company to hitch up with its newly established centralized cell and gene therapy development, manufacturing and commercial capabilities – AlloVir, formerly ViraCyte, which is developing T-cell therapies to treat viruses in immunocompromised patients.
You may also be interested in...
VC deals totaled $8.3bn in the first half of 2019, but the year's total rose to just $11.5bn at the end of September, reflecting only a $3.2bn third quarter gain. Among recent financings, Cygnal emerged from stealth mode with $65m invested to date.
Biopharma companies raised $12.4bn in Q2, largely from follow-on public offerings. In the latest mega-merger of the year, AbbVie spent $63bn on Allergan and its established portfolio. Many of the higher-valued alliances focused on the area of protein degradation.